Supply of medicinal products – Biologics X

Summary

The tender concerns recurring supplies of medicinal products for the contracting authority’s patients, divided into four lots: pembrolizumab, nivolumab, nivolumab/relatlimab, and pertuzumab/trastuzumab. A bidder may submit a separate tender for each lot and may submit for all four lots. The estimated total value is CZK 461,642,000. The submission deadline is 25 September 2026 at 10:00. Electronic submission and electronic invoicing are required, variants are not permitted, and price is the only award criterion with a 100% weighting. The detailed qualification and exclusion requirements must be checked in the procurement documents.